In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Atara Biotherapeutics (ATRA – Research Report), with a price target of $26.00. The company’s shares closed last Wednesday at $12.71.
According to TipRanks.com, Burns is a 5-star analyst with an average return of 23.3% and a 65.3% success rate. Burns covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Springworks Therapeutics.
Currently, the analyst consensus on Atara Biotherapeutics is a Strong Buy with an average price target of $36.25, which is a 186.3% upside from current levels. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $70.00 price target.
Based on Atara Biotherapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $73.51 million. In comparison, last year the company had a GAAP net loss of $66.26 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.